Interleukin-2 therapy in relapsed acute myelogenous leukemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute Myelogenous Leukemia (AML) poses significant challenges, particularly in relapsed-refractory cases and patients not eligible for standard therapies.
• Recombinant interleukin-2 (rIL-2) has emerged as a potential immunotherapeutic agent for hematological malignancies.

Purpose of the Study:

• To assess the efficacy of recombinant interleukin-2 (rIL-2) in patients with relapsed-refractory acute myelogenous leukemia (AML).
• To evaluate rIL-2 in AML patients achieving a second complete remission (CR) who are not candidates for standard treatment.
• To report updated results from Italian studies investigating rIL-2 in AML.

Main Methods:

• A pilot study treated 24 patients with relapsed-refractory AML using a dose-escalating rIL-2 protocol (8-18 x 10(6) IU/m2 daily for 5 days).
• Patients achieving response received subcutaneous maintenance rIL-2.
• A subsequent randomized trial compared rIL-2 to no treatment in 32 AML patients in second CR, though recruitment was limited.

Main Results:

• In the pilot study, 13 patients (54%) achieved CR, with eight maintaining remission on maintenance rIL-2 for a median of 64 months.
• The randomized study showed a trend towards improved disease-free survival in the rIL-2 arm.

Conclusions:

• Recombinant interleukin-2 (rIL-2) demonstrates encouraging activity in AML patients with relapsed-refractory disease and limited blastosis.
• rIL-2 also shows potential in AML patients in second CR.
• These findings support further investigation of high-dose rIL-2 in advanced AML.